Projected Income Statement: Elliptic Laboratories ASA

Forecast Balance Sheet: Elliptic Laboratories ASA

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 -201 -166 -89.7 -57 -43.1 -77.2 -148 -
Change - 17.41% 45.96% 36.45% 24.39% -79.29% -91.71% -
Announcement Date 3/10/22 2/17/23 2/15/24 2/27/25 2/26/26 - - -
1NOK in Million
Estimates

Cash Flow Forecast: Elliptic Laboratories ASA

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 17.61 23.33 25.48 30.72 29.08 33 36 40
Change - 32.46% 9.22% 20.56% -5.32% 13.47% 9.09% 11.11%
Free Cash Flow (FCF) 1 -28.43 -36.08 - - -23.09 19 72 -
Change - -26.91% - - - 182.29% 278.95% -100%
Announcement Date 3/10/22 2/17/23 2/15/24 2/27/25 2/26/26 - - -
1NOK in Million
Estimates

Forecast Financial Ratios: Elliptic Laboratories ASA

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) -4.49% -59.19% -49.06% 19.04% -20.13% 39.31% 48.36% 50.4%
EBIT Margin (%) -17.67% -80.92% -72.81% 3.57% -44.23% 27.49% 38.45% 41.02%
EBT Margin (%) -20.77% -75.49% -68.58% 12.92% -56.68% 27.69% 38.91% -
Net margin (%) -17.7% -61.54% -55.4% 6.79% -135.3% 21.6% 30.35% -
FCF margin (%) -45.11% -69.31% - - -22.47% 8.88% 24.08% -
FCF / Net Income (%) 254.87% 112.62% - - 16.61% 41.11% 79.33% -

Profitability

        
ROA - - - - - - - -
ROE -4.2% -9.7% -11.96% 2.84% - 12.92% 20.91% -

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 27.94% 44.81% 37.29% 23.28% 28.31% 15.42% 12.04% 10.72%
CAPEX / EBITDA (%) -622.48% -75.7% -76.01% 122.29% -140.63% 39.22% 24.9% 21.28%
CAPEX / FCF (%) -61.94% -64.64% - - -125.96% 173.68% 50% -

Items per share

        
Cash flow per share 1 - - - - - - - -
Change - - - - - - - -
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 3.301 3.134 2.929 3.09 - 3.556 4.405 -
Change - -5.06% -6.53% 5.5% - - 23.86% -
EPS 1 -0.11 -0.31 -0.36 0.09 -1.32 0.4272 0.8269 -
Change - -181.82% -16.13% 125% -1,566.67% 132.36% 93.55% -
Nbr of stocks (in thousands) 103,842 104,074 104,838 105,275 105,287 126,337 126,337 -
Announcement Date 3/10/22 2/17/23 2/15/24 2/27/25 2/26/26 - - -
1NOK
Estimates
2026 *2027 *
P/E ratio 8.49x 4.38x
PBR 1.02x 0.82x
EV / Sales 1.76x 1.02x
Yield - -

EPS & Dividend

Y-o-Y evolution of P/E

Year-on-year evolution of the Yield

Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.625NOK
Average target price
13.00NOK
Spread / Average Target
+258.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ELABS Stock
  4. Financials Elliptic Laboratories ASA